CorMedix (CRMD) PT Raised to $12 as RBC Capital Sees a 'Supportive Setup for DefenCath into '25'
Tweet Send to a Friend
RBC Capital analyst Gregory Renza raised the price target on CorMedix (NASDAQ: CRMD) to $12.00 (from $11.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
